• Charlotte Steenblock
  • Peter E.H. Schwarz
  • Barbara Ludwig
  • Andreas Linkermann
  • Paul Zimmet
  • Konstantin Kulebyakin
  • Vsevolod A. Tkachuk
  • Hendrik Lehnert
  • Martin Hrabě de Angelis
  • Hannes Rietzsch
  • Roman N. Rodionov
  • Kamlesh Khunti
  • David Hopkins
  • Andreas L. Birkenfeld
  • Bernhard Boehm
  • Richard I.G. Holt
  • Jay S. Skyler
  • J. Hans DeVries
  • Eric Renard
  • Robert H. Eckel
  • K. George M.M. Alberti
  • Bruno Geloneze
  • Juliana C. Chan
  • Jean Claude Mbanya
  • Henry C. Onyegbutulem
  • Ambady Ramachandran
  • Abdul Basit
  • Mohamed Hassanein
  • Gavin Bewick
  • Giatgen A. Spinas
  • Felix Beuschlein
  • Rüdiger Landgraf
  • Francesco Rubino
  • Geltrude Mingrone
  • Stefan R. Bornstein

Up to 50% of the people who have died from COVID-19 had metabolic and vascular disorders. Notably, there are many direct links between COVID-19 and the metabolic and endocrine systems. Thus, not only are patients with metabolic dysfunction (eg, obesity, hypertension, non-alcoholic fatty liver disease, and diabetes) at an increased risk of developing severe COVID-19 but also infection with SARS-CoV-2 might lead to new-onset diabetes or aggravation of pre-existing metabolic disorders. In this Review, we provide an update on the mechanisms of how metabolic and endocrine disorders might predispose patients to develop severe COVID-19. Additionally, we update the practical recommendations and management of patients with COVID-19 and post-pandemic. Furthermore, we summarise new treatment options for patients with both COVID-19 and diabetes, and highlight current challenges in clinical management.

Original languageEnglish
Pages (from-to)786-798
Number of pages13
JournalThe Lancet Diabetes and Endocrinology
Volume9
Issue number11
DOIs
StatePublished - Nov 2021

    Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

ID: 94439387